IL-6 is a survival prognostic factor in renal cell carcinoma

It has been reported that a high plasmatic concentration of interleukin-6 (IL-6) is correlated to a lack of response to immunotherapy in several malignancies, suggesting that IL-6 was either a marker of tumour aggressiveness or had only a predictive value of response to immunotherapy. To discriminat...

Full description

Saved in:
Bibliographic Details
Published in:Immunology letters 1997-07, Vol.58 (2), p.121-124
Main Authors: Thiounn, Nicolas, Pages, Franck, Flam, Thierry, Tartour, Eric, Mosseri, Véronique, Zerbib, Marc, Beuzeboc, Phillipe, Deneux, Laurent, Fridman, Wolf H., Debré, Bernard
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Biomarkers
Biopterins - analogs & derivatives
Biopterins - blood
C-Reactive Protein - analysis
Carcinoma, Renal Cell - blood
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - therapy
Combined Modality Therapy
Female
Fluorouracil - therapeutic use
Humans
Immunologic Factors - therapeutic use
Immunotherapy
Interferon alpha-2
Interferon-alpha - therapeutic use
Interleukin-6
Interleukin-6 - blood
Kidney Neoplasms - blood
Kidney Neoplasms - drug therapy
Kidney Neoplasms - mortality
Kidney Neoplasms - therapy
Macrophage Colony-Stimulating Factor - blood
Male
Middle Aged
Neoplasm Metastasis
Neopterin
Prognosis
Receptors, Interleukin-2 - blood
Recombinant Proteins
Renal cell carcinoma
Retrospective Studies
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been reported that a high plasmatic concentration of interleukin-6 (IL-6) is correlated to a lack of response to immunotherapy in several malignancies, suggesting that IL-6 was either a marker of tumour aggressiveness or had only a predictive value of response to immunotherapy. To discriminate between these two possibilities, a retrospective study was performed in a series of 19 patients with metastatic renal cell carcinoma who did not respond to IL-2/IFNα/5-FU treatment. Serum levels of IL-6, C-reactive Protein (CRP), soluble IL-2-receptor (sIL-2R), M-CSF and neopterin were assayed before treatment. IL-6 showed a significant correlation with patients median survival time ( P
ISSN:0165-2478
1879-0542
DOI:10.1016/S0165-2478(97)00036-9